Deferasirox: A comprehensive drug profile.

Q1 Pharmacology, Toxicology and Pharmaceutics Profiles of drug substances, excipients, and related methodology Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI:10.1016/bs.podrm.2023.11.001
Mohamed Fawzi Kabil, Maha Nasr
{"title":"Deferasirox: A comprehensive drug profile.","authors":"Mohamed Fawzi Kabil, Maha Nasr","doi":"10.1016/bs.podrm.2023.11.001","DOIUrl":null,"url":null,"abstract":"<p><p>Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2023.11.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
地拉罗司:全面的药物简介。
地拉罗司是诺华公司开发的一种铁螯合剂,用于治疗伴有慢性铁负荷过重的疾病,如β-地中海贫血或镰状细胞疾病。由于它具有高亲和性、特异性和治疗窗口宽等优点,被认为是一线治疗药物。本章介绍了地拉罗司的理化特性、作用模式、药代动力学、治疗应用和合成方法。此外,还包括对其官能团的傅立叶变换红外光谱(FTIR)和核磁共振光谱(NMR)分析。此外,还对选定的分析方法进行了总结,以帮助分析人员对地拉罗司进行常规分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Profiles of drug substances, excipients, and related methodology
Profiles of drug substances, excipients, and related methodology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
13.10
自引率
0.00%
发文量
4
期刊最新文献
Avanafil: A comprehensive drug profile. Deferasirox: A comprehensive drug profile. Duvelisib: A comprehensive profile. Ponatinib: A comprehensive drug profile. Regorafenib: A comprehensive drug profile.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1